Form 4: Tango Therapeutics Director Borisy Acquires Shares and Options

Sentiment:

SEC Form 4 Filing


Director Alexis Borisy reports acquisition of common stock and stock options in Tango Therapeutics.

Summary

  • On June 5, 2024, Alexis Borisy, a director of Tango Therapeutics, acquired 6,250 shares of common stock represented by restricted stock units (RSUs) at a price of $0.00.
  • These RSUs will vest on the earlier of June 5, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service with the Issuer.
  • Borisy also acquired options to purchase 37,500 shares of common stock at an exercise price of $7.41.
  • These options will vest in 12 substantially equal monthly installments starting July 5, 2024, also subject to continuous service with the Issuer.
  • Following these transactions, Borisy beneficially owns 11,250 shares of common stock and options for 37,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares and options suggests confidence, but it's a routine transaction.

Positives

  • A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continuous service with the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Comparison to Industry Standards

  • Comparing the vesting schedules and option grants to similar biotech companies would provide a benchmark for assessing the competitiveness of Tango Therapeutics' executive compensation.
  • Reviewing similar Form 4 filings from companies like Relay Therapeutics, Black Diamond Therapeutics, or Revolution Medicines could offer comparative insights.

Stakeholder Impact

  • Shareholders may view insider purchases as a positive signal.
  • Employees may see this as a sign of management's confidence in the company's future.

Key Dates

DateDescription
06/05/2024Date of transaction: Acquisition of common stock (RSUs) and stock options.
06/05/2025Earliest vesting date for RSUs.
07/05/2024Start date for monthly vesting of stock options.
06/05/2034Expiration date for stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.